<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"><channel rdf:about="http://onlinelibrary.wiley.com/rss/journal/10.1002/(ISSN)1099-1352" xmlns="http://purl.org/rss/1.0/"><title>Journal of Molecular Recognition</title><description> Wiley Online Library : Journal of Molecular Recognition</description><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2F%28ISSN%291099-1352</link><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc</dc:publisher><dc:language xmlns:dc="http://purl.org/dc/elements/1.1/">en</dc:language><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/">© John Wiley &amp; Sons, Ltd.</dc:rights><prism:issn xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">0952-3499</prism:issn><prism:eIssn xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">1099-1352</prism:eIssn><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-07-01T00:00:00-05:00</dc:date><prism:coverDisplayDate xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">July 2013</prism:coverDisplayDate><prism:volume xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">26</prism:volume><prism:number xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">7</prism:number><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">297</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">329</prism:endingPage><image rdf:resource="http://onlinelibrary.wiley.com/store/10.1002/jmr.v26.7/asset/cover.gif?v=1&amp;s=6667c97c184e7a1a78fe63cec503b5072d66075e"/><items><rdf:Seq><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fjmr.2231"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fjmr.2258"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fjmr.2274"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fjmr.2276"/></rdf:Seq></items></channel><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fjmr.2231" xmlns="http://purl.org/rss/1.0/"><title>Issue Information</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fjmr.2231</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Issue Information</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-09T05:11:07.705177-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jmr.2231</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jmr.2231</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fjmr.2231</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Issue Information</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">i</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">iii</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<div class="para" id="jmr2231-para-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>No abstract is available for this article.</p></div>]]></content:encoded><description>No abstract is available for this article.</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fjmr.2258" xmlns="http://purl.org/rss/1.0/"><title>Computational and experimental investigation of DNA repair protein photolyase interactions with low molecular weight drugs</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fjmr.2258</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Computational and experimental investigation of DNA repair protein photolyase interactions with low molecular weight drugs</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Selimcan Azizoğlu, Riza Kizilel, Maja Marušič, Ibrahim Halil Kavakli, Burak Erman, Seda Kizilel</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-09T05:11:07.705177-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jmr.2258</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jmr.2258</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fjmr.2258</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">297</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">307</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>This paper reports the previously unknown interactions between eight low molecular weight commercially available drugs (130–800 Da) and DNA repair protein photolyase using computational docking simulations and surface plasmon resonance (SPR) experiments. Theoretical dissociation constants, <em>K</em><sub>d</sub>, obtained from molecular docking simulations were compared with the values found from SPR experiments. Among the eight drugs analyzed, computational and experimental values showed similar binding affinities between selected drug and protein pairs. We found no significant differences in binding interactions between pure and commercial forms of the drug lornoxicam and DNA photolyase. Among the eight drugs studied, prednisone, desloratadine, and azelastine exhibited the highest binding affinity (<em>K</em><sub>d</sub> = 1.65, 2.05, and 8.47 μM, respectively) toward DNA photolyase. Results obtained in this study are promising for use in the prediction of unknown interactions of common drugs with specific proteins such as human clock protein cryptochrome. Copyright © 2013 John Wiley &amp; Sons, Ltd.</p></div><a title="Link to full-size graphical abstract" class="figZoom" href="http://onlinelibrary.wiley.com/store/10.1002/jmr.2258/asset/image_n/jmr2258-toc-0001.png?v=1&amp;s=5f959359060d3fb80e324f4d649defee9acb4f93" xmlns="http://www.w3.org/1999/xhtml"><img alt="Thumbnail image of graphical abstract" title="Thumbnail image of graphical abstract" src="http://onlinelibrary.wiley.com/store/10.1002/jmr.2258/asset/image_n/jmr2258-toc-0001.png?v=1&amp;s=5f959359060d3fb80e324f4d649defee9acb4f93"/></a>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>This paper reports the previously unknown interactions between eight low molecular weight commercially available drugs and DNA repair protein photolyase using computational docking simulations and surface plasmon resonance experiments. Computational and experimental values showed similar binding affinities between selected drug and protein pairs toward DNA photolyase. Results obtained here are promising for use in the prediction of unknown interactions of common drugs with specific proteins such as human clock protein cryptochrome.
</p><!--Unmatched element: w:blockFixed--></div>]]></content:encoded><description>
This paper reports the previously unknown interactions between eight low molecular weight commercially available drugs (130–800 Da) and DNA repair protein photolyase using computational docking simulations and surface plasmon resonance (SPR) experiments. Theoretical dissociation constants, Kd, obtained from molecular docking simulations were compared with the values found from SPR experiments. Among the eight drugs analyzed, computational and experimental values showed similar binding affinities between selected drug and protein pairs. We found no significant differences in binding interactions between pure and commercial forms of the drug lornoxicam and DNA photolyase. Among the eight drugs studied, prednisone, desloratadine, and azelastine exhibited the highest binding affinity (Kd = 1.65, 2.05, and 8.47 μM, respectively) toward DNA photolyase. Results obtained in this study are promising for use in the prediction of unknown interactions of common drugs with specific proteins such as human clock protein cryptochrome. Copyright © 2013 John Wiley &amp; Sons, Ltd.This paper reports the previously unknown interactions between eight low molecular weight commercially available drugs and DNA repair protein photolyase using computational docking simulations and surface plasmon resonance experiments. Computational and experimental values showed similar binding affinities between selected drug and protein pairs toward DNA photolyase. Results obtained here are promising for use in the prediction of unknown interactions of common drugs with specific proteins such as human clock protein cryptochrome.



</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fjmr.2274" xmlns="http://purl.org/rss/1.0/"><title>Insight into the molecular recognition of spermine by DNA quadruplexes from an NMR study of the association of spermine with the thrombin-binding aptamer</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fjmr.2274</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Insight into the molecular recognition of spermine by DNA quadruplexes from an NMR study of the association of spermine with the thrombin-binding aptamer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Max A. Keniry, E. A. Owen</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-09T05:11:07.705177-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jmr.2274</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jmr.2274</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fjmr.2274</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">308</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">317</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>The preferred residence sites and the conformation of DNA-bound polyamines are central to understanding the regulatory roles of polyamines. To this end, we have used a series of selective <sup>13</sup>C-edited and selective total correlation spectroscopy-edited one-dimensional (1D) nuclear Overhauser effect spectroscopy NMR experiments to determine a number of intramolecular <sup>1</sup>H nuclear Overhauser effect (NOE) connectivities in <sup>13</sup>C-labelled spermine bound to the thrombin-binding aptamer. The results provide evidence that the aptamer-bound spermine adopts a conformation that optimizes electrostatic and hydrogen bond contacts with the aptamer backbone. The distance between the nitrogen atoms of the central aminobutyl is reduced by an increase in the population of <em>gauche</em> conformers at the C6–C7 bonds, which results in either a curved or S-shaped spermine conformation. Molecular modelling contributes insight toward the mode of spermine binding of these spermine structures within the narrow grooves of DNA quadruplexes. In each case, the N5 ammonium group makes hydrogen bonds with two nearby phosphates across the narrow groove. Our results have implications for the understanding of chromatin structure and the rational design of quadruplex-binding drugs. Copyright © 2013 John Wiley &amp; Sons, Ltd.</p></div><a title="Link to full-size graphical abstract" class="figZoom" href="http://onlinelibrary.wiley.com/store/10.1002/jmr.2274/asset/image_n/jmr2274-toc-0001.png?v=1&amp;s=bd39d613c5017db28ec5935bf3b73bf6a0b5fac1" xmlns="http://www.w3.org/1999/xhtml"><img alt="Thumbnail image of graphical abstract" title="Thumbnail image of graphical abstract" src="http://onlinelibrary.wiley.com/store/10.1002/jmr.2274/asset/image_n/jmr2274-toc-0001.png?v=1&amp;s=bd39d613c5017db28ec5935bf3b73bf6a0b5fac1"/></a>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Selective 1D <sup>1</sup>H NOE experiments and molecular modelling indicate that spermine adopts a conformation that matches the curvature of the narrow grooves of the thrombin-binding aptamer. Electrostatic and hydrogen bond contacts with the aptamer backbone determine the location of the preferred residence sites.
</p><!--Unmatched element: w:blockFixed--></div>]]></content:encoded><description>
The preferred residence sites and the conformation of DNA-bound polyamines are central to understanding the regulatory roles of polyamines. To this end, we have used a series of selective 13C-edited and selective total correlation spectroscopy-edited one-dimensional (1D) nuclear Overhauser effect spectroscopy NMR experiments to determine a number of intramolecular 1H nuclear Overhauser effect (NOE) connectivities in 13C-labelled spermine bound to the thrombin-binding aptamer. The results provide evidence that the aptamer-bound spermine adopts a conformation that optimizes electrostatic and hydrogen bond contacts with the aptamer backbone. The distance between the nitrogen atoms of the central aminobutyl is reduced by an increase in the population of gauche conformers at the C6–C7 bonds, which results in either a curved or S-shaped spermine conformation. Molecular modelling contributes insight toward the mode of spermine binding of these spermine structures within the narrow grooves of DNA quadruplexes. In each case, the N5 ammonium group makes hydrogen bonds with two nearby phosphates across the narrow groove. Our results have implications for the understanding of chromatin structure and the rational design of quadruplex-binding drugs. Copyright © 2013 John Wiley &amp; Sons, Ltd.Selective 1D 1H NOE experiments and molecular modelling indicate that spermine adopts a conformation that matches the curvature of the narrow grooves of the thrombin-binding aptamer. Electrostatic and hydrogen bond contacts with the aptamer backbone determine the location of the preferred residence sites.



</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fjmr.2276" xmlns="http://purl.org/rss/1.0/"><title>siRNA associated with immunonanoparticles directed against cd99 antigen improves gene expression inhibition in vivo in Ewing's sarcoma</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fjmr.2276</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">siRNA associated with immunonanoparticles directed against cd99 antigen improves gene expression inhibition in vivo in Ewing's sarcoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">A. L. Ramon, J. R. Bertrand, H. Martimprey, G. Bernard, G. Ponchel, C. Malvy, C. Vauthier</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-09T05:11:07.705177-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jmr.2276</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jmr.2276</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fjmr.2276</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">318</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">329</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>Ewing's sarcoma is a rare, mostly pediatric bone cancer that presents a chromosome abnormality called EWS/Fli-1, responsible for the development of the tumor. <em>In vivo</em>, tumor growth can be inhibited specifically by delivering small interfering RNA (siRNA) associated with nanoparticles. The aim of the work was to design targeted nanoparticles against the cell membrane glycoprotein cd99, which is overexpressed in Ewing's sarcoma cells to improve siRNA delivery to tumor cells. Biotinylated poly(isobutylcyanoacrylate) nanoparticles were conceived as a platform to design targeted nanoparticles with biotinylated ligands and using the biotin–streptavidin coupling method. The targeted nanoparticles were validated <em>in vivo</em> for the targeted delivery of siRNA after systemic administration to mice bearing a tumor model of the Ewing's sarcoma. The expression of the gene responsible of Ewing's sarcoma was inhibited at 78% ± 6% by associating the siRNA with the cd99-targeted nanoparticles compared with an inhibition of only 41% ± 9% achieved with the nontargeted nanoparticles. Copyright © 2013 John Wiley &amp; Sons, Ltd.</p></div><a title="Link to full-size graphical abstract" class="figZoom" href="http://onlinelibrary.wiley.com/store/10.1002/jmr.2276/asset/image_n/jmr2276-toc-0001.png?v=1&amp;s=99fce42bb8e099419df71bd14a410a2117d9fe7a" xmlns="http://www.w3.org/1999/xhtml"><img alt="Thumbnail image of graphical abstract" title="Thumbnail image of graphical abstract" src="http://onlinelibrary.wiley.com/store/10.1002/jmr.2276/asset/image_n/jmr2276-toc-0001.png?v=1&amp;s=99fce42bb8e099419df71bd14a410a2117d9fe7a"/></a>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>siRNA delivered with immunonanoparticles targeted to the cd99 membrane glycoprotein was able to inhibit the expression of the oncogene responsible of Ewing's sarcoma in a model of subcutaneous implanted tumors in mice.
</p><!--Unmatched element: w:blockFixed--></div>]]></content:encoded><description>
Ewing's sarcoma is a rare, mostly pediatric bone cancer that presents a chromosome abnormality called EWS/Fli-1, responsible for the development of the tumor. In vivo, tumor growth can be inhibited specifically by delivering small interfering RNA (siRNA) associated with nanoparticles. The aim of the work was to design targeted nanoparticles against the cell membrane glycoprotein cd99, which is overexpressed in Ewing's sarcoma cells to improve siRNA delivery to tumor cells. Biotinylated poly(isobutylcyanoacrylate) nanoparticles were conceived as a platform to design targeted nanoparticles with biotinylated ligands and using the biotin–streptavidin coupling method. The targeted nanoparticles were validated in vivo for the targeted delivery of siRNA after systemic administration to mice bearing a tumor model of the Ewing's sarcoma. The expression of the gene responsible of Ewing's sarcoma was inhibited at 78% ± 6% by associating the siRNA with the cd99-targeted nanoparticles compared with an inhibition of only 41% ± 9% achieved with the nontargeted nanoparticles. Copyright © 2013 John Wiley &amp; Sons, Ltd.siRNA delivered with immunonanoparticles targeted to the cd99 membrane glycoprotein was able to inhibit the expression of the oncogene responsible of Ewing's sarcoma in a model of subcutaneous implanted tumors in mice.



</description></item></rdf:RDF>